New to Meducation?
Sign up
Already signed up? Log In

Category

0
1
12

Chemotherapy for Second Line Treatment of Non-Small Cell Lung Cancer (NSCLC) (Video)

This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the development of current standards and anticipated benefits vs. risks of second line chemotherapy for advanced non-small cell lung cancer (NSCLC).  
Howard (Jack) West, MD
over 9 years ago
7
1
4

Optimal Treatment of Unresectable Locally Advanced NSCLC (Audio)

This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the evolution of our current standards for chemotherapy for the first line treatment of metastatic non-small cell lung cancer.  
Howard (Jack) West, MD
over 9 years ago
8
1
5

Optimal Treatment of Unresectable Locally Advanced NSCLC (Video)

This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the evolution of our current standards for chemotherapy for the first line treatment of metastatic non-small cell lung cancer.  
Howard (Jack) West, MD
over 9 years ago
13
1
19

Antiangiogenesis in First Line NSCLC (Audio)

This presentation by medical oncologist and lung cancer expert Dr. Jack West introduces the concept of angiogenesis, with a focus on the combination of Avastin (bevacizumab) with chemotherapy for advanced non-small cell lung cancer (NSCLC).  
Howard (Jack) West, MD
over 9 years ago
0
1
13

Antiangiogenesis in First Line NSCLC (Video)

This presentation by medical oncologist and lung cancer expert Dr. Jack West introduces the concept of angiogenesis, with a focus on the combination of Avastin (bevacizumab) with chemotherapy for advanced non-small cell lung cancer (NSCLC).  
Howard (Jack) West, MD
over 9 years ago
1
1
13

Janessa Laskin Interview (Video)

This interview by medical oncologist Dr. Jack West of fellow medical oncologist and lung cancer expert Dr. Janessa Laskin covers the current standards and controversial aspects of post-operative chemotherapy for resected early stage NSCLC.  
Howard (Jack) West, MD
over 9 years ago
2
1
11

Janessa Laskin Interview (Audio)

This interview by medical oncologist Dr. Jack West of fellow medical oncologist and lung cancer expert Dr. Janessa Laskin covers the current standards and controversial aspects of post-operative chemotherapy for resected early stage NSCLC.  
Howard (Jack) West, MD
over 9 years ago
5
1
17

First Line Chemo for Advanced NSCLC (Audio)

This presentation by medical oncologist and lung cancer expert Dr. Jack West describes the evolution of our current standards for chemotherapy for the first line treatment of metastatic non-small cell lung cancer.  
Howard (Jack) West, MD
over 9 years ago
6
1
14

First Line Chemo for Advanced NSCLC (Video)

This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the evolution of our current standards for chemotherapy for the first line treatment of metastatic non-small cell lung cancer.  
Howard (Jack) West, MD
over 9 years ago
5
1
15

What's with the new guidelines for antibiotic prophylaxis?

I was going to talk to Dr. Quinn, but Dr. Yagiela has such a nice chair in his office that I just went into his office instead. He answers some of my questions about the new guidelines for antibiotic prophylaxis. It turns out that we might not actually be saving anyone by doing it  
Carl Jones
over 9 years ago
6
1
22

SABCS 2008 | Case05

ResearchToPractice.com/SABCS_2008 – Second Opinion: Proceedings and Interviews from a 2-Part CME Satellite Symposia Held at the 31st Annual San Antonio Breast Cancer Symposium. Case: 62-year-old woman with a neglected 6-cm, ER/PR-positive, HER2-positive IDC and biopsy-proven lung metastases who refuses chemotherapy. Interviews conducted by Neil Love, MD. Produced by Research To Practice.  
Dr Neil Love
over 9 years ago
13
1
11

BCUTT2 2007 | Adjuvant Chemotherapy

BreastCancerUpdate.com/ThinkTank – Proceedings from a Clinical Investigator “Think Tank.” Adjuvant Chemotherapy. Interviews conducted by Neil Love, MD. Produced by Research To Practice.  
Dr Neil Love
over 9 years ago
9
1
0

BCU Think Tank 1 | 07 - Adjuvant Chemotherapy

www.BreastCancerUpdate.com/ThinkTank – Proceedings from a Clinical Investigator “Think Tank”  
Dr Neil Love
over 9 years ago
4
1
4

BCU Think Tank 2 | 06 - Section 4

Cardiac Toxicity Associated with Anthracycline-Based Chemotherapy (Nonanthracycline Alternatives)  
Dr Neil Love
over 9 years ago
12
1
20

PCUTT1 2007 | Chemotherapy for Hormone-Refractory, Metastatic Disease

ProstateCancerUpdate.com/ThinkTank – Proceedings from a Clinical Investigator “Think Tank.” Chemotherapy for Hormone-Refractory, Metastatic Disease. Interviews conducted by Neil Love, MD. Produced by Research To Practice.  
Dr Neil Love
over 9 years ago
Preview
3
48

Apoptosis and the response to chemotherapy

Apoptosis and response to chemotherapy  
Stephen McAleer
over 6 years ago
Preview
17
323

Chemotherapy

Chemotherapy  
Stephen McAleer
over 6 years ago
Preview
0
57

Osteosarcoma

Osteosarcoma is the most common malignant primary bone tumour. It frequently occurs in late childhood and tends to arise in the metaphyses of the long bones. It may present with pain, swelling or a pathological fracture. Treatment involves resection and chemotherapy. The cure rate is approximately 50% as metastatic disease is not uncommon.  
almostadoctor.com - free medical student revision notes
over 5 years ago
Preview
1
54

Crohn's patient Lizzie Rose loses egg-freezing case - BBC News

A woman who has Crohn's disease loses a legal challenge against a decision to refuse her NHS funding to freeze her eggs before chemotherapy.  
BBC News
over 5 years ago
Preview
1
28

Should doctors prescribe cannabinoids?

The medical use of cannabis was advocated in the United States in the 1970s and 1980s when clinical trials of oral synthetic tetrahydrocannabinol (THC) and other oral synthetic cannabinoids reported efficacy in controlling nausea in patients with cancer who were undergoing chemotherapy.1 Dronabinol (an oral synthetic THC) was approved by the Food and Drug Administration in 1985 for this indication,1 but it was not widely used because patients were unable to titrate doses or disliked its psychoactive effects.1 It is still available in the US, United Kingdom, and the rest of Europe.  
bmj.com
over 5 years ago